Literature DB >> 24434996

New molecule for mobilizing marrow stem cells.

Sakura Hosoba1, Edmund K Waller.   

Abstract

In this issue of Blood, Zhang et al describe an exciting new small-molecule antagonist of CXCL12-CXCR4 binding with a potent ability to mobilize hematopoietic stem cells (HSCs). Further clinical development of this new drug,Me6TREN, may have broad applications in stem-cell mobilization for cancer and in regenerative medicine.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24434996      PMCID： PMC6037285          DOI： 10.1182/blood-2013-12-538249

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  9 in total

1.  Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.

Authors:  Jie Li; Ellie Hamilton; Louette Vaughn; Michael Graiser; Heather Renfroe; Mary Jo Lechowicz; Amelia Langston; Jefferson Mark Prichard; Darlene Anderson; Charise Gleason; Sagar Lonial; Christopher R Flowers; Jonathan L Kaufman; Edmund K Waller
Journal:  Transfusion       Date:  2011-04-14       Impact factor: 3.157

2.  Promotion of collateral growth by granulocyte-macrophage colony-stimulating factor in patients with coronary artery disease: a randomized, double-blind, placebo-controlled study.

Authors:  C Seiler; T Pohl; K Wustmann; D Hutter; P A Nicolet; S Windecker; F R Eberli; B Meier
Journal:  Circulation       Date:  2001-10-23       Impact factor: 29.690

3.  Small molecule Me6TREN mobilizes hematopoietic stem/progenitor cells by activating MMP-9 expression and disrupting SDF-1/CXCR4 axis.

Authors:  Jing Zhang; Xiangliang Ren; Wei Shi; Sihan Wang; Haixu Chen; Bowen Zhang; Zhidong Wang; Yong Zhou; Lin Chen; Rui Zhang; Yang Lv; Junnian Zhou; Xue Nan; Lijuan He; Wen Yue; Yanhua Li; Xuetao Pei
Journal:  Blood       Date:  2013-11-06       Impact factor: 22.113

4.  Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction.

Authors:  Steven M Devine; Ravi Vij; Michael Rettig; Laura Todt; Kiley McGlauchlen; Nicholas Fisher; Hollie Devine; Daniel C Link; Gary Calandra; Gary Bridger; Peter Westervelt; John F Dipersio
Journal:  Blood       Date:  2008-04-21       Impact factor: 22.113

5.  Temporal changes in plerixafor administration and hematopoietic stem cell mobilization efficacy: results of a prospective clinical trial in multiple myeloma.

Authors:  R Donald Harvey; Jonathan L Kaufman; Heather R Johnson; Ajay Nooka; Louette Vaughn; Christopher R Flowers; H Jean Khoury; Mary J Lechowicz; Amelia A Langston; Sagar Lonial; Edmund K Waller
Journal:  Biol Blood Marrow Transplant       Date:  2013-06-10       Impact factor: 5.742

6.  Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.

Authors:  John F DiPersio; Edward A Stadtmauer; Auayporn Nademanee; Ivana N M Micallef; Patrick J Stiff; Jonathan L Kaufman; Richard T Maziarz; Chitra Hosing; Stefan Früehauf; Mitchell Horwitz; Dennis Cooper; Gary Bridger; Gary Calandra
Journal:  Blood       Date:  2009-04-10       Impact factor: 22.113

7.  Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.

Authors:  John F DiPersio; Ivana N Micallef; Patrick J Stiff; Brian J Bolwell; Richard T Maziarz; Eric Jacobsen; Auayporn Nademanee; John McCarty; Gary Bridger; Gary Calandra
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544

8.  Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist.

Authors:  Hal E Broxmeyer; Christie M Orschell; D Wade Clapp; Giao Hangoc; Scott Cooper; P Artur Plett; W Conrad Liles; Xiaxin Li; Barbara Graham-Evans; Timothy B Campbell; Gary Calandra; Gary Bridger; David C Dale; Edward F Srour
Journal:  J Exp Med       Date:  2005-04-18       Impact factor: 14.307

9.  Effect of progenitor cell mobilization with granulocyte-macrophage colony-stimulating factor in patients with peripheral artery disease: a randomized clinical trial.

Authors:  Joseph Poole; Kreton Mavromatis; José N Binongo; Ali Khan; Qunna Li; Mohamed Khayata; Elizabeth Rocco; Matthew Topel; Xin Zhang; Charlene Brown; Matthew A Corriere; Jonathan Murrow; Salman Sher; Stephanie Clement; Khuram Ashraf; Amr Rashed; Tarek Kabbany; Robert Neuman; Alanna Morris; Arshad Ali; Salim Hayek; John Oshinski; Young-sup Yoon; Edmund K Waller; Arshed A Quyyumi
Journal:  JAMA       Date:  2013-12-25       Impact factor: 157.335
  9 in total
  1 in total

1.  SHIPi Enhances Autologous and Allogeneic Hematolymphoid Stem Cell Transplantation.

Authors:  Sandra Fernandes; Robert Brooks; Matthew Gumbleton; Mi-Young Park; Christopher M Russo; Kyle T Howard; John D Chisholm; William G Kerr
Journal:  EBioMedicine       Date:  2015-03-01       Impact factor: 8.143
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.